Pharmaceutical Executive-02-01-2006

While CMS officials praise the CED policy as a way to extend Medicare coverage, patients and industry fear the agency won't reimburse for innovative treatments unless sponsors support post-approval studies.

Is the public ready for an exciting thriller about terrorism, drug counterfeiting, valiant FDA agents, and glamorous women who invite pharma CEOs to come up and look at their drug patents? Sure. Maybe someone should write one.

Attacking articles in medical journals, those ghostwritten by professional medical writers paid by pharmaceutical companies, is the media's latest attempt to taint anything supported, promoted, or approved by Big Pharma.

Our co-promotions have helped us build a strong infrastructure in the US.

Pharma has an enormous backlog of drugs that never made it out of clinical trials. At Gene Logic, these discontinued drugs spell opportunity. Not only are they the foundation of a new business unit at Gene Logic, such failed compounds may become the cornerstone of a new approach to R&D as the industry confronts its latest productivity crisis.

Online strategies aren't monolithic; each must meet the particular goals of the brand in question, and serve the knowledge needs of a specific disease state. That said, experts agree on many of the fundamentals-the 5 "I"s of Internet marketing:

Corporate leaders' short-sighted focus on EPS and analyst expectations leaves the US workforce far behind its international counterparts when it comes to cultivating innovation. It's time we stepped up to the plate.

In Europe, seven of the top-10 injectible drugs are biologics. Generic versions could be priced 25 to 40 percent lower than prescriptions.